{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:28:50Z","timestamp":1791322130289,"version":"4.3.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T00:00:00Z","timestamp":1236816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00105-008-1695-8","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T10:36:18Z","timestamp":1236767778000},"page":"655-657","source":"Crossref","is-referenced-by-count":20,"title":["Prolongierte Psoriasistherapie mit TNF-\u03b1-Antagonisten","Long term treatment of psoriasis with TNF-alpha antagonists"],"prefix":"10.1007","volume":"60","author":[{"given":"L.","family":"Kowalzick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Eickenscheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Komar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schaarschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,12]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 64:1421\u20131426","journal-title":"Ann Rheum Dis"},{"key":"1695_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2230.1994.tb02687.x","volume":"19","author":"Bonifati","year":"1994","unstructured":"Bonifati C, Carducci M, Cordiali Fei P et al (1994) Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients\u2013relationships with disease severity. Clin Exp Dermatol 19:383\u2013387","journal-title":"Clin Exp Dermatol"},{"key":"1695_CR3","first-page":"2130","volume":"32","author":"Chakravarty","year":"2005","unstructured":"Chakravarty EF, Michaud K, Wolfe F (2005) Skin cancer, rheumatoid arthritis and tumor necrosis factor inhibitors. J Rheumatol 32:2130\u20132135","journal-title":"J Rheumatol"},{"key":"1695_CR4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","volume":"56","author":"Fulchiero","year":"2007","unstructured":"Fulchiero GJ, Salvaggio H, Drabick JJ et al (2007) Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor tharapies. J Am Acad Dermatol 56:S65\u2013S67","journal-title":"J Am Acad Dermatol"},{"key":"1695_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2007.08.009","volume":"114","author":"Hueber","year":"2007","unstructured":"Hueber AJ, McInnes IB (2007) Immune regulation in psoriasis and psoriatic arthrtis: recent developments. Immunol Lett 114:59\u201365","journal-title":"Immunol Lett"},{"key":"1695_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0151-9638(07)89187-3","volume":"134","author":"Lebas","year":"2007","unstructured":"Lebas D, Staumont-Sall\u00e9 D, Solau-Gervais E et al (2007) Manifestations cutane\u00e9s observe\u00e9 au cours d\u2019un traitement par anti-TNF alpha: 11 observations. Ann Dermatol Venereol 134:337\u2013342","journal-title":"Ann Dermatol Venereol"},{"key":"1695_CR7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s001050170047","volume":"52","author":"Mrowietz","year":"2001","unstructured":"Mrowietz U, Czech W, Huber J et al (2001) Leitlinien zur Therapie mit Ciclosporin in der Dermatologie. Hautarzt 52:201\u2013204","journal-title":"Hautarzt"},{"key":"1695_CR8","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","volume":"54","author":"Setoguchi","year":"2006","unstructured":"Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor \u03b1 antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757\u20132764","journal-title":"Arthritis Rheum"},{"key":"1695_CR9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"Tyring","year":"2007","unstructured":"Tyring S, Gordon KB, Poulin Y et al (2007) Long-term safety and efficacy of 50\u00a0mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719\u2013726","journal-title":"Arch Dermatol"},{"key":"1695_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1529-8019.2008.00180.x","volume":"21","author":"Tzu","year":"2008","unstructured":"Tzu J, Kerdel F (2008) From conventional to cutting edge: the new era of biologics in the treatment of psoriasis. Dermatol Ther 21:131\u2013141","journal-title":"Dermatol Ther"},{"key":"1695_CR11","first-page":"S1","volume":"45","author":"Watson","year":"2006","unstructured":"Watson KD, Dixon WG, Hyrich KL et al (2006) The influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR Biologics register (BSRBR). Rheumatol 45:S1; i.10","journal-title":"Rheumatol"},{"key":"1695_CR12","first-page":"3948","volume":"47","author":"Winklehake","year":"1987","unstructured":"Winklehake JL, Stampfl S, Zimmerman RJ (1987) Synergistic effects of combination therapy with human recombinant interleukin 2 and tumor necrosis factor in murine tumor models. Cancer Res 47:3948\u20133953","journal-title":"Cancer Res"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1695-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-008-1695-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1695-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:41Z","timestamp":1558582661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-008-1695-8"}},"subtitle":["Entwicklung des malignen Melanoms","Occurrence of malignant melanoma"],"short-title":[],"issued":{"date-parts":[[2009,3,12]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1007\/s00105-008-1695-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,12]]}}}